深圳善康医药科技股份有限公司

Chinese innovative drug company established in October 2017 in Shenzhen, Guangdong and backed by investors including Shenzhen Capital Group, Xiaoxiang Capital, Sinolink Fund and People.cn. Develops, manufactures and sells addiction treatment medicines for relapse into opioid and new-type drug use and for alcohol use disorder, built on a long acting sustained and controlled release implant drug delivery platform that it also applies to central nervous system disease, oncology and infectious disease. Its naltrexone hydrochloride implant was designated a breakthrough therapy by the Center for Drug Evaluation and was approved for marketing in China in June 2024.